Monte Rosa Therapeutics, Inc. (GLUE)
17.13
+0.61
(+3.69%)
USD |
NASDAQ |
Jun 11, 16:00
17.13
0.00 (0.00%)
After-Hours: 16:37
Monte Rosa Therapeutics Gross Profit Margin (Quarterly) : 51.81% for March 31, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 51.81% |
| December 31, 2025 | 24.92% |
| September 30, 2025 | 83.59% |
| June 30, 2025 | 90.84% |
| March 31, 2025 | 97.59% |
| Date | Value |
|---|---|
| December 31, 2024 | 96.60% |
| September 30, 2024 | 77.18% |
| June 30, 2024 | 56.12% |
| March 31, 2024 | -78.29% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Kyntra Bio, Inc. | -10.03% |
| ACADIA Pharmaceuticals, Inc. | 90.75% |
| Alnylam Pharmaceuticals, Inc. | 81.91% |
| Savara, Inc. | -- |
| Vericel Corp. | 72.00% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -42.10% |
| Return on Assets | -27.11% |
| Return on Invested Capital | -37.24% |
| Profit Margin (Quarterly) | -1.06K% |
| Operating Margin (Quarterly) | -1.19K% |
| Return on Net Operating Assets | -237.7% |